Arena Pharmaceuticals Net Income 2006-2021 | ARNA

Arena Pharmaceuticals annual/quarterly net income history and growth rate from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Arena Pharmaceuticals net income for the quarter ending September 30, 2021 was $-0.196B, a 101.47% increase year-over-year.
  • Arena Pharmaceuticals net income for the twelve months ending September 30, 2021 was $-0.583B, a 57.19% increase year-over-year.
  • Arena Pharmaceuticals annual net income for 2020 was $-0.405B, a 201.81% decline from 2019.
  • Arena Pharmaceuticals annual net income for 2019 was $0.398B, a 1452.27% decline from 2018.
  • Arena Pharmaceuticals annual net income for 2018 was $-0.029B, a 67.84% decline from 2017.
Arena Pharmaceuticals Annual Net Income
(Millions of US $)
2020 $-405
2019 $398
2018 $-29
2017 $-91
2016 $-23
2015 $-108
2014 $-61
2013 $-19
2012 $-88
2011 $-111
2010 $-125
2009 $-153
2008 $-239
2007 $-145
2006 $-88
2005 $-77
Arena Pharmaceuticals Quarterly Net Income
(Millions of US $)
2021-09-30 $-196
2021-06-30 $-146
2021-03-31 $-118
2020-12-31 $-122
2020-09-30 $-97
2020-06-30 $-85
2020-03-31 $-100
2019-12-31 $-88
2019-09-30 $-73
2019-06-30 $-61
2019-03-31 $620
2018-12-31 $69
2018-09-30 $-34
2018-06-30 $-32
2018-03-31 $-32
2017-12-31 $-14
2017-09-30 $-32
2017-06-30 $-23
2017-03-31 $-22
2016-12-31 $39
2016-09-30 $-12
2016-06-30 $-27
2016-03-31 $-22
2015-12-31 $-30
2015-09-30 $-26
2015-06-30 $-27
2015-03-31 $-24
2014-12-31 $-32
2014-09-30 $-11
2014-06-30 $7
2014-03-31 $-25
2013-12-31 $-23
2013-09-30 $-17
2013-06-30 $40
2013-03-31 $-19
2012-12-31 $-21
2012-09-30 $-16
2012-06-30 $-22
2012-03-31 $-29
2011-12-31 $-24
2011-09-30 $-23
2011-06-30 $-23
2011-03-31 $-42
2010-12-31 $-28
2010-09-30 $-36
2010-06-30 $-29
2010-03-31 $-31
2009-12-31 $-30
2009-09-30 $-35
2009-06-30 $-38
2009-03-31 $-51
2008-12-31 $-62
2008-09-30 $-56
2008-06-30 $-66
2008-03-31 $-55
2007-12-31 $-41
2007-09-30 $-33
2007-06-30 $-39
2007-03-31 $-32
2006-12-31 $-36
2006-09-30 $-20
2006-06-30 $-19
2006-03-31 $-13
2005-12-31 $-20
2005-09-30 $-16
2005-06-30 $-16
2005-03-31 $-25
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.704B $0.000B
Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their first and only drug approved by any regulatory agency for marketing. BELVIQ was approved by the US Food and Drug Administration, or FDA, for marketing in the United States, and was made available by prescription in June 2013 to adults who are overweight with a comorbidity or obese. They are exploring BELVIQ for possible new indications, using different formulations, and in combination with other drugs.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69